Feb 5 (Reuters) - GSK forecast sales in 2025 to

grow between 3% and 5%, and reported a better-than-expected

fourth quarter earnings, as strength in its HIV and oncology

portfolio offset weakness in its vaccines division.

The company reported core earnings per share of 23.2 pence

on sales of 8.12 billion pounds ($10.13 billion) for the quarter

ended Dec. 31, compared with 19 pence on sales of 7.75 billion

pounds expected by analysts in an LSEG poll.

($1 = 0.8017 pounds)